Analysts have been eager to weigh in on the Healthcare sector with new ratings on NovoCure Ltd (NASDAQ:NVCR) and Agios Pharma (NASDAQ:AGIO).
NovoCure Ltd (NVCR)
Mizuho Securities analyst Difei Yang maintained a Buy rating on NovoCure Ltd today and set a price target of $51. The company’s shares opened today at $33.24.
Yang commented:
“We will send out results as soon as we get enough responses. Difei PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Mizuho Securities USA LLC www.mizuhosecurities.com/usPrice We used a weighted average valuation methodology to value NovoCure with DCF (PT $55 at 50% weight) and EV/Sales (PT $47 at 50% weight) resulting in a $51 PT. In our DCF, we give consideration for Optune in GBM, NSCLC and Mesothelioma.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.2% and a 47.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
NovoCure Ltd has an analyst consensus of Strong Buy, with a price target consensus of $51, a 53.4% upside from current levels. In a report issued on October 25, Wells Fargo also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
Agios Pharma (AGIO)
In a report released today, Leah R. Cann from Oppenheimer maintained a Hold rating on Agios Pharma. The company’s shares opened today at $63.11.
Cann wrote:
“2018 loss per share was $1.63, compared to our estimate of $1.58. This higher loss per share was the result of lower than estimated collaboration revenue and sales of Tibsovo (ivosidenib/AG120). Tibsovo is in the early days of its launch, which appears to be going well. Royalty revenue of $2.0 million was lower than our estimated $2.0 million; however, Idhifa sales of $19.0 million were basically in line with our estimate of $20.0 million, and 46.4% higher than Q2 2018. Operating expenses of $114.4 million were in line with our estimated $115.1 million.”
According to TipRanks.com, Cann is a 3-star analyst with an average return of 1.7% and a 38.5% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.
Agios Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $93.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
